TOP TIERMARKET NEWSWIRE
News & sentiment

BICARA THERAPEUTICS Equity (BCAX) — News & AI sentiment

BICARA THERAPEUTICS Equity (BCAX) news roundup. 9 stories aggregated over the last 30 days. Average 30-day sentiment is 52.9/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 7 sales totalling $3.5M — net selling of $3.5M. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
0
7d stories
0
30d stories
9
avg sentiment 52.9/100
Insider net (90d)
$3.5M
0 buys · 7 sells
Congress (90d)
0
0 buys · 0 sells

BCAX news in the last 24 hours, 7 days, 30 days and 90 days

How much BCAX coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time windowBCAX storiesAvg AI sentimentRead
Last 24 hours0—no coverage
Last 7 days0—no coverage
Last 30 days952.9/100BCAX headlines →
Last 90 days3053.9/100BCAX headlines →

Latest stories on BCAX

Sep 3
Sep 3
Aug 25
Citizens reiterates Bicara Therapeutics stock rating on trial progress
Investing.com Analyst Ratings56 · neutralanalyst
Aug 21
Aug 19
Aug 18
Aug 18
Aug 18
Aug 17
Aug 14
Aug 14
Aug 12
Bicara Therapeutics stock price target raised to $39 by BTIG
Investing.com Analyst Ratings61 · neutralanalyst
Aug 11
Aug 11
Aug 11
Aug 11
Aug 11
Aug 11
Aug 11
Aug 11
Aug 11
Aug 11
Aug 11
Aug 11
Aug 11
Open BCAX in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →